Tempus AI Stock Dips as Earnings on Deck (NASDAQ: TEM) – What To Expect

Tempus AI is scheduled to release its Q1 2025 earnings after market close, with analysts projecting a loss of ($0.27) per share and revenue of $248.13 million. The earnings call, led by CEO Eric Lefkofsky and CFO Jim Rogers, will provide critical insights into the company’s progress following its ambitious 2025 revenue guidance of $1.24 billion (a 79% year-over-year increase).

The Tempus AI stock has fallen 3.5% today leading into the print, despite an impressive rally that has seen the price gain 52.38% YTD. Analysts maintain a “Moderate Buy” consensus rating, with a 12-month price target of $61.08. However, concerns linger over Tempus’s ability to achieve profitability, as its 2024 net loss reached $705.8 million, driven partly by $547.7 million in stock compensation expenses.

Tempus’s Q4 2024 results fell short of expectations, with an adjusted net loss of ($0.18) per share against a ($0.16) estimate. Despite a 35.8% revenue increase to $200.7 million, higher operating expenses (up 6.5% YoY) triggered a 17% stock decline.

The acquisition of Ambry Genetics in February 2025 strengthened Tempus’s genomic testing portfolio, prompting raised 2025 revenue guidance to $1.24 billion. However, the projected $5 million adjusted EBITDA—$1 million below analyst expectations—highlights ongoing profitability challenges.

Recent Highlights – Acquisitions and Partnerships

Tempus and Illumina (NASDAQ: ILMN) announced a collaboration to integrate Illumina’s AI technologies with Tempus’s multimodal data platform, aiming to standardize genomic profiling across oncology, cardiology, neurology, and immunology. This partnership expands Tempus’s reach beyond cancer, positioning it as a cross-therapeutic leader in precision medicine.

Tempus also acquired Deep 6 AI, a clinical trial matching platform integrated with 750 provider sites and 30 million patient records back in March. This $263 million deal enhanced Tempus’s ability to streamline trial recruitment and real-world evidence generation, aligning with its TIME Precision Network for phase I trials.

AstraZeneca and Pathos AI Alliance

A three-way partnership with AstraZeneca and Pathos AI aims to develop a multimodal foundation model for oncology, enhancing biomarker discovery and drug development. This collaboration underscores Tempus’s role in advancing AI-driven clinical insights, driving a 15.8% stock increase on April 23.

Tempus has outperformed broader indices in 2025, rising 52% YTD against the S&P 500’s 4% decline. Analysts attribute this to Tempus’s positioning in the $600 billion AI healthcare market, projected by Precedence Research to grow at a 29.7% CAGR through 2034. William Blair’s Andrew Brackmann notes Tempus’s “long revenue growth runway,” driven by AI adoption in drug development and personalised care.

The stock has come down more than 40% from the 52 week highs set back in February, but has also rallied 40% from the early April lows. Quite the mixed bag with earnings looming large.